Optic Nerve Atrophy: Causes, Treatment and Outlook

Is Optic Nerve Atrophy Serious?

Yes. Optic nerve atrophy means fibers in the optic nerve have been lost, which makes the nerve look pale when an eye doctor examines it. It is a sign of damage rather than a disease in itself, so the most important step is finding the cause. Reduced blood flow is the most common cause. Others include glaucoma, a tumor pressing on the nerve, raised fluid pressure around the brain, inflammation such as optic neuritis, infection, injury, inherited conditions, toxins, some medicines and poor nutrition. Some of these can be treated to stop further loss, which is why unexplained optic nerve atrophy needs a full assessment.

Can Optic Nerve Atrophy Be Reversed?

No. Fibers that have died do not grow back, and the pale nerve does not return to normal. Treatment aims to protect the vision you still have.

Some vision can still return in a few situations, because a damaged nerve may contain fibers that are not working but have not died. When a tumor pressing on the nerve is removed, vision improves in some people, especially if the nerve has not yet wasted away: in one surgical series, 49.4% of treated eyes improved, about a quarter stayed the same and 22.9% got worse, and the average gain in sharpness was less than one line on the eye chart. When the cause is a missing nutrient, the outlook can be excellent if it is replaced in time. Once atrophy is well established, recovery is minimal.

Treatment for Optic Nerve Atrophy

No medicine or operation repairs a wasted (atrophic) optic nerve. Treatment targets the cause to stop or slow the loss of more fibers. Depending on the cause, that can mean lowering eye pressure in glaucoma, removing a tumor, relieving raised fluid pressure around the brain, stopping a medicine or toxin that is harming the nerve, or replacing a missing vitamin. Surgery helps only when it treats one of these causes.

Glasses cannot fix vision lost to optic nerve atrophy, but low vision aids can make daily tasks easier. A low vision specialist can help with magnifiers, special or tinted lenses, lighting, and the larger text and higher contrast settings on phones and computers. If only one eye is affected, protective glasses help keep the other eye safe.

Netra Restoration Therapy is supportive care alongside this treatment. It does not regrow the optic nerve or restore lost vision.

New Treatments for Optic Nerve Atrophy in 2026

No new treatment can yet restore a nerve that has wasted away. The research that is furthest along targets specific causes:

• Leber hereditary optic neuropathy (LHON): idebenone has been approved in the European Union since 2015 for adults and adolescents with vision loss from LHON (ask your specialist whether it is available where you live), and gene therapy for one form of LHON is being tested in clinical trials.
• Dominant optic atrophy, the most common inherited optic nerve disorder: an experimental medicine called STK-002, designed to raise the low levels of the OPA1 protein behind the condition, began its first clinical trial in 2026, in the UK and Germany, in people aged 6 to 55.
• Glaucoma: in small trials, nicotinamide (vitamin B3) improved a measure of retinal function, and larger trials are under way. A participant in one trial had liver injury, so take it only within a supervised trial.
• Regrowing the optic nerve: candidate treatments have been tested in animals but have not yet been shown to work in people.

Be wary of clinics that sell "stem cell" treatments for optic nerve disease. The FDA says these products are not approved to treat blindness and has received reports of blindness, tumors and infections. Ask your eye doctor whether a clinical trial might suit you.

A Supportive Program Alongside Medical Care for Optic Nerve Atrophy

Optic nerve atrophy refers to visible pallor and structural loss of the optic nerve caused by degeneration of retinal ganglion cell axons. The optic nerve is not a passive cable. It is central nervous system tissue made of more than one million retinal ganglion cell axons that transmit visual information from the retina to the brain. When those axons are injured, compressed, deprived of blood supply, inflamed, poisoned, genetically vulnerable, or metabolically stressed, the nerve can gradually lose tissue volume and appear pale on examination.

Because optic nerve atrophy is a final pathway rather than one single diagnosis, the most important clinical question is not only “what does the optic nerve look like?” but “what biological process injured the optic nerve, and is it still active?” StatPearls describes optic atrophy as optic nerve shrinkage caused by degeneration of retinal ganglion cell axons and notes that the term is often used to describe the end result of many optic neuropathies. In practice, patients may arrive with optic atrophy after glaucoma, non-arteritic ischemic optic neuropathy, traumatic optic neuropathy, compressive lesions, inflammatory optic neuritis, toxic or nutritional optic neuropathy, hereditary optic neuropathy, mitochondrial disorders, or unexplained optic nerve damage.

Netra Restoration Therapy, or NRT, is the clinic's integrative care program for chronic optic nerve disease. For optic nerve atrophy, NRT does not regrow a lost optic nerve, reverse fiber loss or restore lost vision, and it has not been shown to protect the remaining nerve. It is offered as supportive care alongside your eye doctor, with attention to circulation, nutrition, sleep, stress and other whole-body factors.

A pale optic nerve may contain fibers that are already lost and fibers that are damaged but still working. Treating the cause, such as lowering eye pressure in glaucoma, relieving pressure on the nerve or replacing a missing vitamin, gives those remaining fibers the best chance. Your doctors may also want to manage blood pressure, blood sugar, sleep apnea, smoking and alcohol. NRT offers supportive care with everyday factors such as sleep, stress and nutrition alongside that care.

NRT does not replace neuro-ophthalmology, retinal imaging, glaucoma monitoring, neurological evaluation, or urgent care for sudden vision changes. Optic nerve atrophy is the visible result of an earlier or ongoing problem, such as poor blood flow, raised eye pressure, inflammation, pressure on the nerve or a missing nutrient, which is why finding and treating the cause comes first.

Why Treatment for Optic Nerve Atrophy Should Be Multi-Factorial

Optic nerve atrophy should be approached as a multifactorial condition because optic nerve injury rarely depends on one pathway alone. Even when the original cause is known, such as ischemia, glaucoma, trauma, inflammation, compression, toxicity, or hereditary mitochondrial vulnerability, the downstream damage often converges on shared biological mechanisms: impaired axonal transport, mitochondrial energy failure, oxidative stress, neuroinflammation, glutamate excitotoxicity, vascular dysregulation, neurotrophin deprivation, and regulated cell death pathways.

A single-mechanism approach may miss the reality of optic nerve biology. Retinal ganglion cells have long axons, high energy demand, complex mitochondrial transport requirements, and dependence on blood supply and neurotrophic signaling. The unmyelinated portion of retinal ganglion cell axons near the optic nerve head is especially metabolically demanding. This helps explain why the optic nerve can be vulnerable to hypoxia, mitochondrial dysfunction, perfusion instability, and oxidative stress.

Ocular Blood Flow and Perfusion Instability

The optic nerve head depends on a delicate microvascular supply. Reduced perfusion, vascular dysregulation, nocturnal hypotension, anemia, sleep apnea, diabetes, hypertension, or endothelial dysfunction may reduce the ability of optic nerve tissue to maintain normal metabolism. In ischemic optic neuropathy and glaucoma-related optic atrophy, perfusion pressure and microvascular regulation are especially relevant.

Poor blood flow to the optic nerve is a common cause of optic nerve damage, as in ischemic optic neuropathy, and it may also play a part in glaucoma. Not every case of optic atrophy is caused by poor blood flow, but conditions such as high or very low blood pressure, diabetes and sleep apnea can matter, and your doctors may want to manage them.

Mitochondrial Dysfunction and Energy Failure

Retinal ganglion cells use a lot of energy, so problems with mitochondria, the energy-producing parts of cells, can make them more easily damaged. The optic nerve is formed by retinal ganglion cell axons, which carry visual signals from the eye to the brain. In optic nerve atrophy, loss or injury of these axons can follow ischemia, inflammation, compression, toxic or nutritional injury, glaucoma, or inherited disease. The optic nerve—not the retinal pigment epithelium—is the central tissue involved. NRT is offered as supportive care while the underlying cause is evaluated and treated; it has not been shown to protect the optic nerve.

Oxidative Stress and Reactive Oxygen Species Injury

Oxidative stress is a major shared mechanism in optic nerve disease. Retinal ganglion cells are vulnerable to reactive oxygen species because of their high metabolic activity, long axons, and dependence on mitochondrial function. A 2021 review in Antioxidants discussed oxidative stress in ocular diseases associated with retinal ganglion cell degeneration, including glaucoma, hereditary optic atrophy, inflammatory optic neuritis, ischemic optic neuropathy, traumatic optic neuropathy, and drug toxicity.

Redox balance may be influenced by mitochondrial health, nutrition, inflammation, vascular oxygen delivery, sleep, metabolic syndrome, toxin exposure, and systemic inflammatory load.

Neuroinflammation and Glial Activation

Optic nerve atrophy often involves more than neuron loss. Astrocytes, microglia, Muller cells, cytokines, and immune mediators can shape the injury environment. Neuroinflammation may initially be protective, but chronic inflammatory signaling can amplify oxidative stress, disrupt axonal support, and contribute to retinal ganglion cell vulnerability.

Inflammatory load may be influenced by metabolic health, gut-immune signaling, vascular dysfunction, stress physiology, sleep quality, and nutritional status. NRT has not been shown to reduce inflammation in the optic nerve.

Neurotrophin Deprivation: BDNF and NGF

Retinal ganglion cells depend on neurotrophic support. Brain-derived neurotrophic factor, or BDNF, is one of the most studied neurotrophins in optic nerve research. Experimental studies have shown that disrupted retrograde axonal transport of BDNF and its receptor TrkB can occur in optic nerve injury models, suggesting that neurotrophin deprivation may contribute to retinal ganglion cell loss. NGF and related receptors are also studied in healthy and injured retina.

Boosting these nerve growth signals has helped nerve cells survive in laboratory and animal studies. Early, small trials in people have had mixed results, so this is not yet a proven treatment. NRT draws on this research for supportive care; it has not been shown to protect the remaining optic nerve tissue.

Excitotoxicity and Glutamate-Mediated Stress

Excitotoxicity refers to neuronal injury caused by excessive glutamate signaling and calcium overload. In optic neuropathy research, excitotoxic pathways are often discussed alongside mitochondrial dysfunction, oxidative stress, impaired axonal transport, and inflammation. Excitotoxicity may not explain every case of optic atrophy, but it is relevant to retinal ganglion cell vulnerability under stress.

A systems-based approach considers excitotoxic stress as part of a larger network: poor blood flow, mitochondrial dysfunction, oxidative stress, inflammation, and impaired cellular repair can all make retinal ganglion cells less able to tolerate excitatory load.

Ferroptosis and Lipid Peroxidation

Ferroptosis is an iron-dependent form of regulated cell death involving lipid peroxidation. It is increasingly studied in retinal ganglion cell death, glaucoma, optic nerve crush models, and retinal ischemia-reperfusion injury. Experimental studies have suggested that inhibition of ferroptosis can promote retinal ganglion cell survival in optic nerve injury models, although this remains largely preclinical.

In plain terms, ferroptosis is a form of cell death driven by iron and damage to fats in cell membranes. It is an important emerging research area, but it is not a proven treatment target for optic atrophy.

Whole-Body Terrain and Systemic Drivers

Optic nerve health may be influenced by systemic factors, including diabetes, hypertension, sleep apnea, anemia, nutritional deficiencies, autoimmune inflammation, toxin exposure, chronic stress, and metabolic dysfunction. These factors may affect perfusion, oxygen delivery, oxidative stress, inflammation, mitochondrial function, and neurovascular resilience. This is where integrative ophthalmology adds value. It looks beyond the optic disc photograph and asks what body-wide factors may be weakening the optic nerve environment.

Key Biological Mechanisms in Optic Nerve Atrophy

Retinal Ganglion Cell Axon Degeneration

Optic atrophy ultimately reflects injury to retinal ganglion cell axons. These axons carry visual information from the eye to the brain. Once axons are lost, the optic nerve becomes thinner and paler. The key clinical challenge is identifying the cause of axonal injury and supporting any remaining viable retinal ganglion cells.

Axonal Transport Dysfunction

Retinal ganglion cells depend on axonal transport to move mitochondria, proteins, signaling molecules, and neurotrophic factors along the optic nerve. Disruption of axonal transport can deprive the cell body of survival signals and impair energy distribution. Research on BDNF transport in optic nerve injury models has made axonal transport a major focus in neuroprotection research.

Mitochondrial Vulnerability

Retinal ganglion cells are among the most mitochondria-dependent neurons in the body. OPA1-related dominant optic atrophy and Leber hereditary optic neuropathy demonstrate how mitochondrial dysfunction can selectively affect the optic nerve. Acquired optic neuropathies may also involve mitochondrial impairment after ischemic, inflammatory, toxic, or pressure-related injury.

Oxidative Stress

Reactive oxygen species can damage mitochondrial DNA, cell membranes, proteins, and axonal structures. Oxidative stress can also activate inflammatory pathways and regulated cell death. Because mitochondrial dysfunction and oxidative stress often reinforce each other, both are major research targets.

Neuroinflammation

Microglia, astrocytes, cytokines, and complement-related immune signaling may influence optic nerve degeneration. Chronic neuroinflammation can make the local environment less supportive for retinal ganglion cell survival. Inflammation is therefore a major research target.

Vascular Insufficiency and Hypoxia

Optic nerve tissue depends on stable blood supply. Hypoperfusion, nocturnal hypotension, endothelial dysfunction, vasospasm, sleep apnea, diabetes, and vascular disease may compromise oxygen and nutrient delivery. Vascular support is especially relevant in ischemic optic neuropathy and glaucoma-related optic atrophy.

Neurotrophin Deficiency

BDNF, NGF and other nerve growth signals help nerve cells survive and repair. Reduced delivery or signaling of these factors may contribute to retinal ganglion cell death.

Excitotoxicity

Excessive glutamate signaling can increase calcium influx, mitochondrial stress, and neuronal injury. Excitotoxicity is best viewed as one part of a broader optic nerve stress network rather than a single independent cause.

Ferroptosis and Lipid Injury

Emerging research suggests iron-dependent lipid peroxidation may contribute to retinal ganglion cell loss in optic neuropathy models. This links optic nerve degeneration to oxidative stress, mitochondrial dysfunction, iron metabolism, and antioxidant reserve.

Systemic Metabolic and Nutritional Stress

Nutritional deficiencies, toxin exposure, diabetes, anemia, autoimmune disease, and chronic inflammatory states may affect the optic nerve. A comprehensive approach should evaluate systemic contributors when clinically appropriate.

What Is Netra Restoration Therapy for Optic Nerve Atrophy?

Netra Restoration Therapy is a multi-part integrative ophthalmology program that looks at several aspects of health at the same time. For optic nerve atrophy, it is supportive care alongside your eye doctor. It does not reverse established fiber loss or restore lost vision.

NRT for optic nerve atrophy may include individualized combinations of acupuncture, traditional Chinese Medicine principles, Ayurvedic medicine principles, herbal and botanical support, nutritional strategies, functional medicine evaluation, stress management and lifestyle guidance. These are offered as supportive care. The approach is personalized because optic nerve atrophy may arise from different causes in different patients.

The focus depends on the cause. In glaucoma, the eye doctor's pressure-lowering treatment and monitoring come first. After ischemic optic neuropathy, sleep apnea, blood pressure and other vascular risks may need attention. In toxic or nutritional optic neuropathy, exposures and nutrient levels need checking. In hereditary optic atrophy, genetic testing and specialist advice matter.

NRT does not replace diagnostic evaluation. Optic atrophy can occasionally reflect serious causes such as compression along the visual pathway, inflammatory disease, vascular events, nutritional deficiency, or toxicity. New, worsening, asymmetric, painful, or unexplained vision loss requires timely evaluation by an appropriate eye-care or medical professional. NRT functions as an adjunctive support strategy after appropriate diagnosis and risk assessment.

NRT does not replace your eye doctor's care. For optic nerve atrophy, it pays attention to the areas below, which are research themes rather than proven treatment targets:

• Ocular and optic nerve head blood flow
• Perfusion stability and vascular regulation
• Retinal ganglion cell resilience
• Mitochondrial energy production and quality control
• Oxidative stress reduction and redox balance
• Inflammatory and immune balance
• Neurotrophin activity, including BDNF and NGF pathways
• Axonal transport and nerve signaling terrain
• Retinal metabolism and glial support
• Whole-body factors that influence optic nerve health

How NRT Fits Alongside Optic Nerve Atrophy Care

Blood Flow

Retinal ganglion cells and the optic nerve head need a steady supply of oxygen. Integrative assessment may consider blood pressure patterns, sleep apnea risk, stress, metabolic health and general vascular health, and point out anything your doctors may want to check. NRT has not been shown to improve blood flow to the optic nerve or protect the remaining nerve tissue.

Mitochondrial Energy

Mitochondrial dysfunction is one of the strongest shared themes in optic neuropathy research. NRT pays attention to nutrition, sleep and metabolic health as part of general supportive care; it has not been shown to improve mitochondrial function in the optic nerve. In hereditary optic neuropathies, mitochondrial biology is especially central; in acquired optic neuropathies, mitochondrial injury may be a downstream amplifier of damage.

What Neuroprotection Research Is Looking At

Neuroprotection means protecting retinal ganglion cells, the nerve cells whose fibers make up the optic nerve, from further damage. Researchers are studying blood flow, energy production in these cells, oxidative stress, nerve growth signals, inflammation and other targets. Apart from treating the cause, such as lowering eye pressure in glaucoma, the only medicine approved for this purpose is idebenone, for one inherited condition (LHON), and only in the European Union. No other neuroprotective treatment has yet been proven to work in people. NRT draws on these ideas for supportive care, but it is not a proven neuroprotective treatment.

Research on BDNF and NGF

BDNF and NGF matter because retinal ganglion cells rely on these growth signals to survive. In laboratory and animal studies, BDNF can help these cells survive, but turning this into lasting benefit for people has proved difficult. This research is background for NRT's supportive care, not evidence that NRT protects the optic nerve or restores vision.

Inflammation

Optic nerve degeneration can be worsened by chronic inflammatory signaling. NRT offers diet, stress, sleep and lifestyle guidance as part of general health support; it has not been shown to reduce inflammation in the optic nerve.

Oxidative Stress and Diet

Oxidative stress is common to glaucoma, hereditary optic atrophy, ischemic optic neuropathy, inflammatory optic neuropathy, traumatic optic neuropathy, and toxic injury. NRT offers nutrition guidance, such as eating foods rich in antioxidants, along with sleep and lifestyle support, as part of general health care; it has not been shown to reduce oxidative damage to the optic nerve.

Excitotoxicity and Ferroptosis

Excitotoxicity and ferroptosis are important because they describe ways retinal ganglion cells can die under metabolic and oxidative pressure. These mechanisms are still being studied, and much of the evidence comes from laboratory and animal research. They are not yet proven treatment targets, and NRT does not claim to act on them.

Whole-Body Health

The optic nerve is influenced by systemic physiology. Gut inflammation, poor nutrient absorption, metabolic syndrome, sleep disruption, toxin exposure, chronic stress, and vascular dysfunction can all increase biological stress. NRT looks at the patient as a whole person and can point out general health issues, such as a possible deficiency, for your doctors to check.

Translating TCM and Ayurveda into Modern Biological Language

Traditional Chinese Medicine may describe optic nerve atrophy using patterns such as Qi Deficiency, Blood Stasis, Liver Blood Deficiency, Kidney Essence Deficiency, Yin Deficiency, or internal heat. In modern interpretation, these may loosely parallel impaired circulation, reduced metabolic reserve, tissue undernourishment, chronic degenerative vulnerability, inflammatory load, or poor repair capacity. These are conceptual parallels, not exact scientific equivalents. Ayurvedic concepts such as Vata, Pitta, Kapha, Rakta Dhatu, Majja Dhatu, and Ojas may be interpreted as frameworks related to nervous system stability, inflammation, circulation, tissue nourishment, neuroendocrine regulation, and resilience. NRT uses these traditional frameworks alongside modern ophthalmic science.

Understanding Herbal Medicine as Multi-Target Systems Biology

Modern research increasingly studies herbal medicine through systems biology and network pharmacology. A single herb may contain dozens or hundreds of compounds, and a formula may contain hundreds or thousands of phytochemicals. In the laboratory, these compounds may affect vascular regulation, oxidative stress, inflammatory cytokines, mitochondrial function, neurotrophin signaling and endothelial health. No herb has been proven to help optic nerve atrophy, and herbs can interact with medicines, so tell your doctors about any you take.

Frequently Asked Questions on Optic Nerve Atrophy

Selected References for Scientific Support

• Optic Atrophy - StatPearls, NCBI Bookshelf. Updated 2024. Describes optic atrophy as optic nerve shrinkage caused by retinal ganglion cell axon degeneration and reviews major causes and clinical evaluation. https://www.ncbi.nlm.nih.gov/sites/books/NBK559130/
• Lambuk L, et al. Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma and Optic Neuropathy. 2022. Reviews BDNF as a retinal ganglion cell survival factor and discusses translational challenges. https://pmc.ncbi.nlm.nih.gov/articles/PMC9163364/
• Kang EYC, et al. Role of Oxidative Stress in Ocular Diseases Associated with Retinal Ganglion Cell Degeneration. Antioxidants. 2021. Reviews oxidative stress in glaucoma, hereditary optic atrophy, optic neuritis, ischemic optic neuropathy, traumatic optic neuropathy, and toxicity. https://pmc.ncbi.nlm.nih.gov/articles/PMC8750806/
• Yang TH, et al. Mitochondria in Retinal Ganglion Cells: Unraveling the Mechanisms of Mitochondrial Dysfunction in Optic Neuropathies. International Journal of Molecular Sciences. 2024. Summarizes mitochondrial roles in retinal ganglion cell health and optic neuropathies. https://pmc.ncbi.nlm.nih.gov/articles/PMC11354650/
• Wong DCS, et al. OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets. 2023. Reviews OPA1-related mitochondrial fragmentation, impaired ATP generation, and retinal ganglion cell vulnerability. https://pmc.ncbi.nlm.nih.gov/articles/PMC10645107/
• Pease ME, et al. Obstructed Axonal Transport of BDNF and Its Receptor TrkB in Experimental Glaucoma. Investigative Ophthalmology & Visual Science. 2000. Landmark work linking impaired neurotrophin transport with retinal ganglion cell injury. https://iovs.arvojournals.org/article.aspx?articleid=2199903
• Guo M, et al. Inhibition of Ferroptosis Promotes Retinal Ganglion Cell Survival in Experimental Optic Nerve Injury Models. 2022. Supports ferroptosis as an emerging mechanism in RGC death in preclinical models. https://pmc.ncbi.nlm.nih.gov/articles/PMC9679710/
• Pietrucha-Dutczak M, et al. The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cell Degeneration. Frontiers in Neuroscience. 2018. Reviews neurotrophic factors, redox regulation, and cell death pathways in RGC survival. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00834/full
• Munemasa Y, Kitaoka Y. Molecular Mechanisms of Retinal Ganglion Cell Degeneration in Glaucoma and Optic Nerve Injury. 2013. Reviews multifactorial RGC degeneration mechanisms relevant to optic neuropathy. https://pmc.ncbi.nlm.nih.gov/articles/PMC3540394/
• Zhi FY, et al. Manual Acupuncture for Optic Atrophy: A Systematic Review and Meta-analysis. 2019. Reviews acupuncture evidence for optic atrophy while noting limitations in study quality. https://pmc.ncbi.nlm.nih.gov/articles/PMC6332962/
• Cleveland Clinic. Optic Atrophy. Updated July 14, 2023.
• American Association for Pediatric Ophthalmology and Strabismus. Optic Nerve Atrophy. Updated March 2023.
• Bulters DO, Shenouda E, Evans BT, Mathad N, Lang DA. Visual recovery following optic nerve decompression for chronic compressive neuropathy. Acta Neurochirurgica. 2009;151(4):325-334.
• Hall WA, Gurnani B. Compressive Optic Neuropathy. StatPearls. Updated November 30, 2025.
• Jefferis JM, Hickman SJ. Treatment and outcomes in nutritional optic neuropathy. Current Treatment Options in Neurology. 2019;21(1):5.
• National Eye Institute. Low Vision. Updated November 25, 2025.
• National Organization for Rare Disorders. Leber Hereditary Optic Neuropathy. Updated February 2, 2023.
• European Medicines Agency. Raxone (idebenone). EU authorisation September 8, 2015.
• Stoke Therapeutics. Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002 for the Treatment of Autosomal Dominant Optic Atrophy. February 11, 2026.
• Hui F, Tang J, Williams PA, et al. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clinical and Experimental Ophthalmology. 2020;48(7):903-914.
• Shukla AG, Cioffi GA, Liebmann JM. Drug-induced liver injury during a glaucoma neuroprotection clinical trial. Journal of Glaucoma. 2024;33(8):e58-e59.
• Goldberg JL, Guido W, and the AGI Workshop Participants. Report on the National Eye Institute Audacious Goals Initiative: Regenerating the Optic Nerve. National Eye Institute; April 2015, updated October 22, 2025.
• US Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Content current as of April 8, 2024.
• Ahmad SS, Blair K, Kanukollu VM. Optic Atrophy. StatPearls. Updated 2024.
• Margolin E, Blair K, Shemesh A. Toxic and Nutritional Optic Neuropathy. StatPearls. Updated 2023.